Showing results (31-40 of 1,216) with videos related to
Sort By:
Pageof 122
Glia|August 26, 2018
Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal lossSvetlana Gushchina, Gareth Pryce, Ping K Yip, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine inductionRachel Harry, Matthew Gegg, Deborah Hankey, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 31, 2006
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 miceLynsey G Bilsland, James R T Dick, Gareth Pryce, et al.Journal of Neuroimmunology|June 9, 2005
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosisGareth Pryce, Janet K O'Neill, J Ludovic Croxford, et al.Acta Neuropathologica Communications|December 25, 2013
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosisDavid W Hampton, Andrea Serio, Gareth Pryce, et al.Journal of Neuroimmunology|November 27, 2007
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosisJ Ludovic Croxford, Gareth Pryce, Samuel J Jackson, et al.The American Journal of Pathology|November 5, 2002
A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis : inflammation versus degenerationZubair Ahmed, Anne I Doward, Gareth Pryce, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2002
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosisClaire E Walters, Gareth Pryce, Deborah J R Hankey, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 12, 2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disordersEva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.Plos One|October 17, 2013
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosisSofia Sisay, Gareth Pryce, Samuel J Jackson, et al.Pageof 122